KMDA vs. GRCL, SBTX, ATAI, VSTM, IMRX, AKBA, NVCT, SGMT, RPHM, and LFCR
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Gracell Biotechnologies (GRCL), Silverback Therapeutics (SBTX), Atai Life Sciences (ATAI), Verastem (VSTM), Immuneering (IMRX), Akebia Therapeutics (AKBA), Nuvectis Pharma (NVCT), Sagimet Biosciences (SGMT), Reneo Pharmaceuticals (RPHM), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry.
Kamada vs.
Kamada (NASDAQ:KMDA) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.
34.1% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 28.0% of Gracell Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Kamada has higher revenue and earnings than Gracell Biotechnologies. Gracell Biotechnologies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Kamada currently has a consensus target price of $11.00, indicating a potential upside of 112.77%. Gracell Biotechnologies has a consensus target price of $14.20, indicating a potential upside of 367.11%. Given Gracell Biotechnologies' higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than Kamada.
Kamada has a net margin of 2.35% compared to Gracell Biotechnologies' net margin of 0.00%. Kamada's return on equity of 7.42% beat Gracell Biotechnologies' return on equity.
Kamada received 279 more outperform votes than Gracell Biotechnologies when rated by MarketBeat users. Likewise, 64.88% of users gave Kamada an outperform vote while only 60.00% of users gave Gracell Biotechnologies an outperform vote.
In the previous week, Gracell Biotechnologies had 1 more articles in the media than Kamada. MarketBeat recorded 1 mentions for Gracell Biotechnologies and 0 mentions for Kamada. Gracell Biotechnologies' average media sentiment score of 1.59 beat Kamada's score of 0.00 indicating that Gracell Biotechnologies is being referred to more favorably in the news media.
Kamada has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Gracell Biotechnologies has a beta of -1.38, indicating that its stock price is 238% less volatile than the S&P 500.
Summary
Kamada beats Gracell Biotechnologies on 12 of the 17 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools